Clinical Evaluation of the QuantiFERON CMV Assay
NCT03502161 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 8
Last updated 2020-09-16
Summary
Validate the use of the device in the clinical setting for assessing the risk of CMV Infection in SOT recipients after the completion of antiviral prophylaxis.
Conditions
- CMV
Interventions
- DEVICE
-
QuantiFERON CMV Assay
Assay to measure cell-mediated immune function using QuantiFERON CMV assay.
Sponsors & Collaborators
-
QIAGEN Gaithersburg, Inc
lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-11-15
- Primary Completion
- 2020-05-15
- Completion
- 2020-06-30
Countries
- United States
Study Locations
More Related Trials
-
WP16302 A Bioequivalence Study Comparing Ganciclovir From the Valganciclovir Syrup Formulation and the Commercial Valganciclovir 450mg Tablet (Valcyte®) at a Dose of 900mg in Kidney Transplant Recipients
NCT00275314 ·Status: TERMINATED ·Phase: PHASE3
-
CMV Infection in Adolescent Males
NCT00302029 ·Status: TERMINATED
-
Cytomegalovirus-Specific Response Measured by QuantiFeron® and Overall Immunologic Response Measured by ImmuKnow® in Lung Transplant Patients CMV-positive
NCT02076971 ·Status: COMPLETED
-
Cell Mediated Immunity for Secondary Prophylaxis in CMV SOT Patients
NCT02370758 ·Status: COMPLETED ·Phase: NA
-
A Study of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft Recipients
NCT01753167 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age
NCT05575492 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV)
NCT01376778 ·Status: COMPLETED ·Phase: PHASE3
-
Assessing the Risk of CMV Infection of the Renal Transplant About R + by Cellular Immunity Analyzed by the QuantiFERON ®-CMV Test.
NCT02064699 ·Status: TERMINATED
-
Prophylactic Therapy for Cytomegalovirus in Liver Transplant Recipients
NCT00364052 ·Status: UNKNOWN
-
A Study on Cytomegalovirus (CMV) Infection Outcomes Among Solid Organ Transplant (SOT) Participants in Europe and Canada
NCT05576805 ·Status: COMPLETED
-
A Study in Adolescent Females to Explore Cytomegalovirus Infection
NCT01691820 ·Status: COMPLETED ·Phase: NA
-
Safety Study of Four Chimera Cytomegalovirus (CMV) Vaccines in Healthy Adult Males 30-50 Years of Age
NCT01195571 ·Status: COMPLETED ·Phase: PHASE1
-
Detection of Cytomegalovirus Virus in Neonates
NCT03251261 ·Status: COMPLETED
-
A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine
NCT04975893 ·Status: COMPLETED ·Phase: PHASE2
-
Neonatal CMV-Ganciclovir Follow-up Study
NCT00031421 ·Status: COMPLETED
-
Evaluation of the Long-term Persistence of GlaxoSmithKline (GSK) Biologicals' Candidate Cytomegalovirus (CMV) Vaccine
NCT01357915 ·Status: COMPLETED ·Phase: NA
-
A Study on Cytomegalovirus (CMV) Infection Outcomes Among Hematopoietic Stem Cell Transplant (HSCT) Participants in Europe and Canada
NCT05571137 ·Status: COMPLETED
-
PREDICT Cytomegalovirus (CMV)
NCT03300882 ·Status: COMPLETED
-
Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 in Healthy Adults
NCT04232280 ·Status: COMPLETED ·Phase: PHASE2
-
Treatment of Cytomegalovirus (CMV) Infections With Viral-Specific T Cells
NCT03798301 ·Status: TERMINATED ·Phase: PHASE1
-
IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
NCT00294515 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Valcyte (Valganciclovir) CMV Prophylaxis After Renal Transplantation
NCT00372229 ·Status: COMPLETED ·Phase: PHASE3
-
Cytomegalovirus Risk in Seropositive Kidney Transplant Recipients Stratified by Quantiferon-CMV
NCT03858907 ·Status: UNKNOWN
-
A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infection
NCT06615921 ·Status: COMPLETED
-
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.
NCT05683457 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2